Cocrystal Pharma (COCP)
(Delayed Data from NSDQ)
$2.72 USD
+0.19 (7.51%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $2.65 -0.07 (-2.57%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Cocrystal Pharma, Inc. [COCP]
Reports for Purchase
Showing records 21 - 34 ( 34 total )
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progress Anticipated; Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
CC-42344 Influenza Antiviral Candidate Enters Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Two COVID-19 Antiviral Lead Candidates Selected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Antiviral Programs Gaining Prominence; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Delisting Risk Low, in Our View; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Proprietary Inhibitors Show Broad Antiviral Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 and Influenza a Pipeline Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
CDI-45205 Shows Activity Against Delta Variant; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Novel Influenza Antiviral CC-42344 Entering Clinical Testing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
CDI-45205 Shows Variant Antiviral Activity; Modulating PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19-Targeting Portfolio Expansion; Pipeline Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Progress With Pipeline Initiatives; Solid Balance Sheet; Modulating PT to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cocrystal Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Cracking the Code in Viral Infection Therapy; Initiating at Buy and $5.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R